Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

Literature DB >> 2570430

Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

S R Marder¹, J W Hubbard, T Van Putten, K K Midha.

Abstract

The authors review the literature regarding the pharmacokinetics of long-acting injectable neuroleptic drugs (LINS). There are important differences between LINS and oral neuroleptics that affect their pharmacokinetics. By avoiding first pass metabolism in gut and liver, LINS result in lower circulating concentrations of metabolites than are found after oral administration. In addition, LINS take more time to reach a stable steady state than their oral counterparts. The clinical significance of these pharmacokinetic properties is discussed. The authors recommend that when patients are being changed from oral neuroleptics to LINS, that this conversion be done gradually over several months.

Entities: Species

Mesh：

Substances：

Year: 1989 PMID： 2570430 DOI： 10.1007/BF00441937

Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN： 0033-3158 Impact factor: 4.530

46 in total

1. Radioimmunoassay for fluphenazine sulfoxide in human plasma.

Authors: K K Midha; E M Hawes; J W Hubbard; G McKay; G Rauw; M S Sardessai; M Aravagiri; M D Moore
Journal: J Pharmacol Methods Date: 1988-03

Review 2. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.

Authors: D A Johnson
Journal: J Clin Psychiatry Date: 1984-05 Impact factor: 4.384

Review 3. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

Authors: R J Baldessarini; B M Cohen; M H Teicher
Journal: Arch Gen Psychiatry Date: 1988-01

4. Prolonged pharmacologic activity of neuroleptic drugs.

Authors: J W Hubbard; D Ganes; K K Midha
Journal: Arch Gen Psychiatry Date: 1987-01

5. Theoretical and practical importance of plasma levels of haloperidol. Correlations with clinical and computerized EEG data.

Authors: R P De Buck; N Zelaschi; C Gilles; J Durdu; H Brauman
Journal: Prog Neuropsychopharmacol Date: 1981

6. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.

Authors: G E Hogarty; N R Schooler; R Ulrich; F Mussare; P Ferro; E Herron
Journal: Arch Gen Psychiatry Date: 1979-11

7. Enzymatic hydrolysis of haloperidol decanoate and its inhibition by proteins.

Authors: K Nambu; H Miyazaki; Y Nakanishi; Y Oh-e; Y Matsunaga; M Hashimoto
Journal: Biochem Pharmacol Date: 1987-05-15 Impact factor: 5.858

8. Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo.

Authors: A Jørgensen
Journal: Eur J Clin Pharmacol Date: 1980-10 Impact factor: 2.953

9. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.

Authors: A Rifkin; F Quitkin; C J Rabiner; D F Klein
Journal: Arch Gen Psychiatry Date: 1977-01

Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

1. Radioimmunoassay for fluphenazine sulfoxide in human plasma.

Review 2. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.

Review 3. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

4. Prolonged pharmacologic activity of neuroleptic drugs.

5. Theoretical and practical importance of plasma levels of haloperidol. Correlations with clinical and computerized EEG data.

6. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.

7. Enzymatic hydrolysis of haloperidol decanoate and its inhibition by proteins.

8. Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo.

9. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.

10. Destruction of chlorpromazine during absorption in the rat in vivo and in vitro.

Review 1. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Review 2. The Black Book of Psychotropic Dosing and Monitoring.

3. Structural changes by sulfoxidation of phenothiazine drugs.

Review 4. Pharmacokinetic optimisation of the treatment of psychosis.